BioPharmX To Present Phase 2b Clinical Trial Data at National DEF Essential Resource Meeting 2017

MENLO PARK, Calif., July 13, 2017 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2b research of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Dermatology Education Foundation's Essential Resource Meeting, DERM 2017, being held July 20-23 in Las Vegas. e data, to be shared in a poster entitled "Safety, Efficacy and Patient Satisfaction of BPX-01 2% Minocycline Topical Gel for Acne Vulgaris," will show the 2% formulation of BPX-01 reduced acne lesions in phase 2b subjects by 59% (compared to 44% for vehicle) and delivered at least a two-grade reduction in investigator global assessment (IGA) and clear to almost clear for 25% of subjects. The study also found BPX-01 was generally well tolerated, without any serious drug-related adverse events experienced, photosensitivity, staining or skin discoloration.

A survey of study participants showed that 86% would use BPX-01 again and 79% said it was easy to use and apply the drug.

"The high efficacy rate and good tolerability scores suggest that the novel BPX-01 may be a promising treatment for acne, a skin condition that has not benefited from innovative new therapies for many decades," said Hilary Baldwin, M.D., board-certified dermatologist and Medical Director of The Acne Treatment and Research Center, Morristown, NJ.  "We are particularly enthusiastic that patients told us they would use BPX-01 again, since a serious impediment to effective acne care today is that patients often fail to use their prescribed acne medications consistently, often because they are associated with undesirable side effects. BPX-01 presented no such side effects."

BPX-01 data will also be discussed by prominent dermatology thought leaders during two podium presentations at the national dermatology meeting on July 21:

• "Acne and Rosacea: New Therapeutic Agents," a presentation by Drs. Linda Stein Gold and Hilary Baldwin, at 1:15 p.m.
• "Poster Highlights Discussion," led by Joe Gorelick and Dr. Julie Harper, at 4:30 p.m.

BPX-01 is the first topical gel formulation of minocycline that can penetrate the skin to deliver the antibiotic to the the pilosebaceous unit, where acne-associated bacterium, P. acnes resides. It is also the first and only stable hydrophilic and non-oil-based topical gel with fully solubilized minocycline. The company's studies are designed to confirm whether BPX-01 will effectively treat acne with lower dosages of the antibiotic with no or fewer adverse side effects.

The American Academy of Dermatology calls acne the "most common skin condition in the United States," affecting up to 50 million Americans. The disease can cause permanent scarring, low self-esteem, depression and anxiety.

About BioPharmX^® Corporation
BioPharmX Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty pharmaceutical company, which seeks to provide products through proprietary platform technologies for prescription, over-the-counter (OTC), and supplement applications in the health and wellness markets, including dermatology and women's health. To learn more about BioPharmX, visit www.BioPharmX.com.

Forward-Looking Statements
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. This press release contains forward-looking statements about the company's expectations, plans, intentions, and strategies, including, but not limited to, statements regarding the safety and medical effects of BPX-01, the effect BPX-01 may have on the treatment of acne, the commencement and results of future trials of BPX-01 and the size of such trials, continued and consistent results in future tests of BPX-01 and absence of side effects of future use of BPX-01. These forward-looking statements may be identified by words such as "plan," "expect," "anticipate," "believe" or similar expressions that are intended to identify such forward-looking statements.

These forward-looking statements involve risks and uncertainties, as well as assumptions, which, if they do not fully materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties include those described in the company's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the period ended Jan. 31, 2017 and quarterly report on Form 10-Q for the period ended April 30, 2017. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements included in this news release are made only as of the date hereof, and the company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

BioPharmX is a registered trademark of BioPharmX, Inc.

View original content with multimedia:http://www.prnewswire.com/news-releases/biopharmx-to-present-phase-2b-clinical-trial-data-at-national-def-essential-resource-meeting-2017-300487673.html

SOURCE BioPharmX Corporation